HomeCompareTHYCY vs ABBV

THYCY vs ABBV: Dividend Comparison 2026

THYCY yields 2.16% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $69.5K in total portfolio value
10 years
THYCY
THYCY
● Live price
2.16%
Share price
$5.43
Annual div
$0.12
5Y div CAGR
26.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.2K
Annual income
$3,607.02
Full THYCY calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — THYCY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHYCYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THYCY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THYCY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THYCY
Annual income on $10K today (after 15% tax)
$183.32/yr
After 10yr DRIP, annual income (after tax)
$3,065.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $18,800.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THYCY + ABBV for your $10,000?

THYCY: 50%ABBV: 50%
100% ABBV50/50100% THYCY
Portfolio after 10yr
$70.0K
Annual income
$14,666.37/yr
Blended yield
20.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

THYCY
No analyst data
Altman Z
1.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THYCY buys
0
ABBV buys
0
No recent congressional trades found for THYCY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHYCYABBV
Forward yield2.16%3.12%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR26.4%40.6%
Portfolio after 10y$35.2K$104.7K
Annual income after 10y$3,607.02$25,725.73
Total dividends collected$13.1K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: THYCY vs ABBV ($10,000, DRIP)

YearTHYCY PortfolioTHYCY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,973$272.61$11,559$438.51$586.00ABBV
2$12,094$353.36$13,494$640.86$1.4KABBV
3$13,401$460.09$15,951$945.97$2.5KABBV
4$14,941$602.23$19,152$1,413.89$4.2KABBV
5$16,780$793.18$23,443$2,146.38$6.7KABBV
6$19,007$1,052.33$29,391$3,321.96$10.4KABBV
7$21,746$1,408.10$37,948$5,265.87$16.2KABBV
8$25,171$1,903.07$50,795$8,596.74$25.6KABBV
9$29,535$2,602.23$71,034$14,549.41$41.5KABBV
10$35,209$3,607.02$104,715$25,725.73$69.5KABBV

THYCY vs ABBV: Complete Analysis 2026

THYCYStock

Taiheiyo Cement Corporation engages in the cement, mineral resources, environmental, and construction materials businesses in Japan and internationally. The company's Cement segment offers ordinary Portland cement, specialty cement, soil stabilizers, and ready-mixed concrete. Its Mineral Resources segment sells limestone aggregate products comprising course and fine aggregate used in ready-mixed concrete, and aggregate used in concrete products and civil engineering; sandstone and andesite as aggregate materials; quicklime, slaked lime, filler, silica, and silica powder; and hollow ceramics, sepiolite, wollastonite, and kaolin, as well as recycles surplus construction soil. The company's Environmental segment recycles used tires, waste plastics, paper sludge, waste casting sand, other industrial waste, surplus soil from water purification, sewage sludge, dredging sludge, and other wastes discarded from municipalities, as well as engages in the CFC treatment and building waste treatment plants; develops and commercializes environmental recycling technologies, including ash washing system and applied kiln system; supplies flue gas desulfurization materials, such as calcium carbonate to coal-fired power plants; and sells slag powder and other inorganic materials, coal, heavy oil, and other fuels, as well as chemicals and gypsum. Its Construction Materials segment produces precast concrete products; promenades, interlocking blocks, and concrete housing products; acoustic panels used to reduce construction noise; and fireproof covering materials used in tunnels. The company's Other Businesses segment leases land for office buildings, commercial stores, leisure facilities, distribution warehouses, and other structures, as well as develops land for residential housing; and engages in the data processing, transportation and warehouse, engineering, chemical products, and sports businesses. Taiheiyo Cement Corporation was incorporated in 1881 and is headquartered in Tokyo, Japan.

Full THYCY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this THYCY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THYCY vs SCHDTHYCY vs JEPITHYCY vs OTHYCY vs KOTHYCY vs MAINTHYCY vs JNJTHYCY vs MRKTHYCY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.